FCDO is abreast of the latest evidence on malaria prevention and treatment. We will continue to work with partners to assess evidence as it is released.<\/p>
FCDO remains committed to funding research to develop tools to prevent, detect and treat malaria. This has resulted in successes such as the world's first child-friendly antimalarial drug which is estimated to have saved more than a million lives since 2009.<\/p>
Global health remains a top priority for UK ODA and we will continue to be a major contributor and a force for good in leading international action.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"} } , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"} , "answeringMemberPrinted" : {"_value" : "Wendy Morton"} , "dateOfAnswer" : {"_value" : "2021-10-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-10-18T15:50:42.127Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "208"} , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "date" : {"_value" : "2021-09-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Malaria: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, whether he has received representations on the potential role of anti-body drugs in tackling malaria.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "53898"} , {"_about" : "http://data.parliament.uk/resources/1135744", "AnsweringBody" : [{"_value" : "Ministry of Defence"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135744/answer", "answerText" : {"_value" : "
Adverse events are reported to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow card scheme and can be undertaken by a healthcare professional or the individual experiencing the adverse effect. The demographics required by the Yellow card scheme do not include the occupation of the subject, so military personnel are not uniquely identified.<\/p>
The aims of the "713/MoDREC/15" study do not include assessing whether individuals or their healthcare professional reported side effects to the MHRA or to follow-up whether any person experiencing side effects required any form of treatment, including an assessment of whether suitable treatment was available. Data collated in the study is self-reported by individuals and any symptoms reported may not necessarily be related to the anti-malarial taken.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"} } , "answeringMemberPrinted" : {"_value" : "Earl Howe"} , "dateOfAnswer" : {"_value" : "2019-07-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-08T16:39:39.247Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "11"} , "answeringDeptShortName" : {"_value" : "Defence"} , "answeringDeptSortName" : {"_value" : "Defence"} , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Malaria: Drugs"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government whether the health and wellbeing of all participants in the Surgeon-General\u2019s 2016\u201317 research study on anti-malarial chemoprophylaxis (Ref: 713/MoDREC/15) was monitored to ensure that all adverse events occurring during the study were reported to the Medicines and Healthcare products Regulatory Agency (MHRA); whether participants have been monitored following the study to ensure that any adverse events that have occurred since are being reported to the MHRA; and what assessment they have made of whether suitable treatment is available to those participants suffering adverse events.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"} } , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"} ], "uin" : "HL16837"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }